您好，欢迎来到试剂信息网！ [登录] [免费注册]
试剂信息网
发布求购
位置：首页 > 产品库 > JNJ4796
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
JNJ4796
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
JNJ4796图片
CAS NO:2241664-16-2
包装与价格：
包装价格(元)
10mg电议
25mg电议

产品介绍
JNJ4796 是具有口服活性的流感病毒融合性抑制剂，通过抑制血球凝集素 (HA) 介导的融合来中和甲型流感病毒。JNJ4796 和广泛中和抗体 (bnAbs) 的功能类似。
Cas No.2241664-16-2
分子式C28H27N9O3
分子量537.57
溶解度DMSO : 100 mg/mL (186.02 mM; Need ultrasonic)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

JNJ4796 is an oral active fusion inhibitor ofinfluenza virus, neutralizing influenza A group 1 viruses by inhibitinghemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs)[1].

Like bnAb CR6261, the mechanism of action of JNJ4796 is demonstrated to be based on inhibition of the pH-sensitive conformational change of HA that triggers fusion of the viral and endosomal membranes and release of the viral genome into the host cell[1].

Oral administration of JNJ4796 protects mice from lethal challenge of 25 times the median lethal dose (LD50) of H1N1 A/Puerto Rico/8/1934 virus. Doses of 50 and 10 mg/kg of JNJ4796 twice daily, initiated one day before challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved[1].
Oral doses of JNJ4796 results in dose-dependent efficacy after a sublethal viral challenge (LD90), with twice daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival[1].

Animal Model:Female BALB/cAnNCrl mice intranasally infected with 2 × 25 μL of 25 × LD50or 1 × LD90of H1N1 A/Puerto Rico/8/34 dissolved in sterile phosphate buffered saline (D-PBS)[1]
Dosage:50 and 10 mg/kg.
Administration:Oral twice daily for 7 days.
Result:Resulted in 100% survival at day 21 in comparison to the less potent compound JNJ8897.